Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Nivolumab Combinations in Castration-resistant Metastatic Prostate Cancer
2017-001626-17Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of nivolumab in prostate cancer (PCa) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Objective Response Rate (ORR). Started Nov 2017; status: completed.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2017-001626-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001626-17.